Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07326566 · ClinicalTrials.gov registry record · Phase 2
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
A Phase 2 study of Glioma and Brain Cancer, sponsored by Black Diamond Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 162
- Enrollment target
- 1
- Study location
NCT07326566 is a Phase 2 study of Glioma and Brain Cancer that is actively recruiting participants, run by Black Diamond Therapeutics. The registered enrollment target is 162 participants, below the 208-participant average among 87 other Glioma trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07326566, a Phase 2 study of Glioma and Brain Cancer, is actively recruiting participants, sponsored by Black Diamond Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following questions: * How much of the study drugs (silevertinib combined with temozolomide) should be given to participants with GBM? * What are the side effects participants have when taking the study drug (silevertinib combined with temozolomide)? * Can the study drug (silevertinib combined with temozolomide) help participants with GBM live longer without disease progression compared to treatment with temozolomide alone?
Conditions Studied
Interventions
- DRUG silevertinib in combination with temozolomide
- DRUG temozolomide (TMZ)
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2026-04 |
| Est. Completion | 2029-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07326566
The ClinicalTrials.gov registry entry for NCT07326566 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 87 other Glioma trials with a reported enrollment target (22% lower). The listed sponsor is Black Diamond Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Glioma appearing as the primary indexed condition, and to 2 interventions - of which silevertinib in combination with temozolomide is the first listed.
NCT07326566 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07326566 about?
NCT07326566 is a clinical study titled "Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII". The purpose of this study is to see if combining silevertinib with temozolomide after surgery and radiotherapy helps treat newly diagnosed glioblastoma (GBM) better than using temozolomide alone in the maintenance setting. Specifically, this study is being done to find answers to the following ques...
What is the current status of trial NCT07326566?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2026-04. Estimated completion is 2029-03.
What conditions does trial NCT07326566 study?
This clinical trial studies the following conditions: Glioma, Brain Cancer, GBM, Central Nervous System Diseases, Glioblastoma (GBM).
What interventions are being tested in trial NCT07326566?
The interventions under investigation include: silevertinib in combination with temozolomide (DRUG), temozolomide (TMZ) (DRUG).
Who is sponsoring clinical trial NCT07326566?
This trial is sponsored by Black Diamond Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07326566 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Pembrolizumab, Olaparib, and Temozolomide for People With Glioma
RECRUITING · Phase 2
-
Methimazole in Patients With Progressive Glioblastoma
RECRUITING · Phase 2
-
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
RECRUITING · Phase 2
-
A Study Utilizing Escitalopram in Glioma Patients
RECRUITING · Phase 2
-
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.